Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cangma Huadu Granules is a Traditional Chinese Medicine (TCM) formulation developed by the Beijing Hospital of Traditional Chinese Medicine specifically for the treatment of mild COVID-19. The formulation is designed based on TCM principles to clear heat, detoxify, and resolve dampness. It has been utilized as a hospital-made preparation in Beijing during the COVID-19 pandemic to alleviate symptoms such as fever, cough, and fatigue in patients with mild infections. The name likely refers to its primary herbal components, such as Atractylodes lancea (Cangzhu) and Ephedra (Mahuang).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Cangma Huadu Granules.